Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Tables)

v2.4.0.8
Summary of Significant Accounting Policies (Tables)
 6 Months Ended
Jun. 30, 2013
Accounting Policies [Abstract]  
Inventories

Inventories are comprised of implantable tissue, Avance® Nerve Graft, AxoGuard® Nerve Connector, AxoGuard® Nerve Protector, and supplies that are valued at the lower of cost (first-in, first-out) or market and consist of the following:

 

     June 30,
2013 		     December 31,
2012 		 
     (unaudited)         

Finished goods

    $ 2,405,237       $ 2,143,176   

Work in process

      198,030         145,156   

Raw materials

      972,512         862,777   
  

 

 

     

 

 

  
   $ 3,575,779       $ 3,151,109   
  

 

 

     

 

 

  
Share-Based Compensation

The Company used the following weighted-average assumptions for options granted during the six months ended June 30:

 

Six months ended June 30,

    2013     2012  

Expected term (in years)

      4.0        4.0   

Expected volatility

      84.10 %      118.11 %

Risk free rate

      0.60 %      0.63 %

Expected dividends

      0.0 %     0.0 %